Avenue therapeutics receives complete response letter from the fda for iv tramadol

New york, june 14, 2021 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue”), a company focused on the development of intravenous (“iv”) tramadol for the u.s. market, today announced that it has received a second complete response letter (“crl”) from the u.s. food and drug administration (“fda”) regarding its new drug application (“nda”) seeking approval for iv tramadol.
ATXI Ratings Summary
ATXI Quant Ranking